Skip to main content

Table 2 Results of the discrete choice experiment

From: A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)

General model All participants (n = 28) Patient Association (n = 4) Physicians (n = 6) Health economics (n = 7) Hospital pharmacy (n = 5) Health Authorities (n = 6)
Beta (coefficient) Standard error Z-value p. value Odds ratio Rel. Imp (%) Rel. Imp (%) Rel. Imp (%) Rel. Imp (%) Rel. Imp Rel. Imp (%)
HRQoL − 1.011 0.069 − 14.742  < 0.001 0.364 23.53 14.27 20.55 25.11 22.35 21.83
Efficacy − 0.614 0.067 − 9.175  < 0.001 0.541 14.64 13.23 15.05 8.86 17.70 10.73
Availability of treatment alternatives − 0.552 0.065 − 8.466  < 0.001 0.576 13.51 11.00 9.92 6.00 16.43 19.39
Disease severity 0.514 0.065 7.907  < 0.001 1.672 12.62 13.93 11.62 14.82 8.89 5.27
Avoided costs − 0.452 0.064 − 7.020  < 0.001 0.636 11.21 11.55 10.45 13.06 9.27 6.90
Age of target population − 0.499 0.103 − 4.854  < 0.001 0.607 7.75 6.55 8.20 2.15 8.22 10.16
Safety (seriousness of AE) − 0.303 0.103 − 2.956 0.003 0.738 4.72 8.70 5.49 4.15 1.50 1.10
Quality of evidence − 0.151 0.063 − 2.392 0.017 0.860 3.82 3.91 7.21 2.44 4.50 1.05
Target population − 0.125 0.064 − 1.952 0.051* 0.883 3.12 2.62 0.38 2.13 3.61 7.26
Economic burden of the disease 0.103 0.065 1.568 0.117 1.108 2.50 3.15 3.78 2.97 2.43 2.78
Cost of treatment 0.072 0.066 1.086 0.278 1.074 1.73 2.34 2.57 4.72 0.79 4.88
Cost-effectiveness − 0.054 0.103 − 0.518 0.604 0.948 0.83 7.57 2.83 9.46 2.04 6.15
Safety (AE frequency) − 0.002 0.103 − 0.017 0.986 0.998 0.03 1.19 1.73 4.12 2.25 2.52
  1. *p = 0.042 (< 0.05) in the reduced model. In bold, relevant criteria for decision-making. AE: adverse events; HRQoL: health-related quality of life; Rel. Imp.: relative importance